Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-19
DOI
10.1007/s00262-021-02960-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications
- (2020) Yu-Jie Zhou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
- (2020) Ziyu Li et al. Gastric Cancer
- Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
- (2020) Ziyu Li et al. Science Advances
- Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections
- (2020) Min Ye et al. Cancer Cell International
- Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
- (2020) Iléana Corbeau et al. Cancers
- c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors
- (2020) Antonia Strippoli et al. Cancers
- Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
- (2019) Tadayoshi Hashimoto et al. Gastric Cancer
- Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray
- (2019) Hedvig Elfving et al. Clinical Lung Cancer
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis
- (2019) Fangxuan Li et al. Cancer Medicine
- Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
- (2018) Yang Li et al. Scientific Reports
- Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status
- (2018) Lei Wang et al. Cancer Medicine
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognostic role of tumor-infiltrating lymphocytes in gastric cancer
- (2018) Jung Soo Lee et al. MEDICINE
- Neutrophils in cancer: prognostic role and therapeutic strategies
- (2017) Alberto Ocana et al. Molecular Cancer
- Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy
- (2017) Reza Nejati et al. PANCREAS
- PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
- (2017) Lihu Gu et al. PLoS One
- Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
- (2016) Nozomu Fuse et al. Gastric Cancer
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
- (2016) Elizabeth D Thompson et al. GUT
- Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications
- (2016) Ruri Saito et al. MODERN PATHOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach
- (2015) Eva Fuentes et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer
- (2015) FEN WANG et al. Oncology Letters
- Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience
- (2014) Esther Diana Rossi et al. CANCER CYTOPATHOLOGY
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- Treatment of gastric cancer
- (2014) Michele Orditura WORLD JOURNAL OF GASTROENTEROLOGY
- Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy
- (2013) Hailong Jin et al. World Journal of Surgical Oncology
- Epigenetic silencing ofId4identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis
- (2012) Maurizio Martini et al. CANCER
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started